RMD

Published 29 August 2023

ResMed is an interesting one.

Sales growth remains very strong. They’ve had a tailwind from a key competitor recall these past few years.

And so they’ve sold a lot of masks and devices, limited really only by their own ability to ramp up production.

They’ve not been immune to cost pressures, and that of mix shift in product.

Described below, everything from component costs to warranties, to whether the device is an APAP or CPAP or one of newer, higher margin versions, like AirSense 11. Whilst there’s a lot under the hood, the basic idea is: does the airflow vary based on your needs, or just drill into you? You pay more for auto-titrating devices.

[update, from a subsequent presentation, at the BoA global healthcare conference in September, in which they call out the margin splits more clearly].

Further, additional pressures below COGS are also there, in the form of SGA. But the big one is the gross margin stuff, which then flows through to affect the EBITDA margin.

Now, when does that key competitor Philips Respironics come back? Management doesn’t know. Or if they do know, they aren’t saying. Management do point out that they are present in other markets that didn’t have the recall, and RMD are still winning there.

And so, you are left with a difficult-to-quantify overhang. Is it material? Does it matter? Will they be rational?

Still, given that the recall has dragged on for a long time, and the replacement products needed recalling too (e.g. they recalled the product that they replaced the first recall with), it is a big hit to their reputation, which surely means some degree of share is ceded.

The next key bit is about these miracle weight loss drugs like WeGovy or Semaglutide. GLP-1s. You take the drug, you don’t eat, you get skinny, you suffer less OSA (obstructive sleep apnoea). It’s a big deal. So, here’s the Q on the call.

And much later down, mgmt’s answer. They think GLP-1s are too expensive, for now.

Here’s the grim economics. $480K on the GLP-1 side, coming from dosage over 40yrs * 12 months per year * $1000/per round, which = lots.

Vs some $13K lifetime cost for CPAP (device, masks etc).

On adherence, CPAP is remarkably well treated. It is “non-invasive” however much it might not look it. The President Biden tagline below is also good.

The next key concern is inventory. That’s quite a high balance, same if you scale it for sales. The worry is GM’s already under pressure could be exacerbated if there’s a need to move stock of this magnitude.

I would be inclined to worry more if the balance sheet was weak, or the multiple unduly high. But RMD is neither (with the share price having de-rated quite a bit).

Important Information: This document has been prepared by Aequitas Investment Partners Pty Ltd ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of AIP FS Pty Ltd ABN 49 680 982 478 (Australian Financial Services Licensee no. 700016) and is for distribution within Australia to wholesale clients only.

This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.

Past performance is not a reliable indicator of future performance.

General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.

Taxation warning: Aequitas is not authorised to provide tax (financial) advice and is not a registered tax agent. Investors should seek their own tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law. We recommend that you consult a registered tax agent or a tax specialist to confirm your taxation position.

Share this post

Do you want to stay ahead of the market?

Sign up to receive daily updates on investment topics and monthly updates on portfolios directly from the desks of our Joint Chief Financial Officers.
Stay ahead of the market and receive adviser insights straight to your inbox.